Orphan Therapeutics Accelerator Forms Key Partnerships to Support Ultra-Rare Disease Treatments
Thursday, April 24, 2025
The Orphan Therapeutics Accelerator (OTXL), a non-profit biotechnology organisation dedicated to completing development and bringing treatments for ultra-rare diseases to market, has announced a series of new partnerships. These collaborations include global biotech and pharmaceutical companies focused on rare diseases, as well as partners in contract development and manufacturing (CDMO), contract research (CRO), and AI-powered platforms.
Chiesi and BIAL have joined as the first Founding Members of OTXL, providing funding and strategic support. They will play a key role in selecting and advancing a group of initial development programmes, which are expected to be announced soon.
To help reduce costs and improve efficiency, Landmark Bio will support chemistry, manufacturing, and controls (CMC) development, while Uncommon Cures will assist in optimising clinical trial operations. DVLP Medicines is contributing a full drug development platform through an early access scheme that leverages AI tools to perform complex planning and analysis quickly and cost-effectively. Vibe Bio will offer AI-driven solutions to assess and manage potential treatment candidates, streamlining clinical development and commercial planning.
These partners are the first members of Orphan ClinDevNet, a connected network of organisations offering support across clinical and commercial stages.
OTXL was set up in June 2024 in response to increasing challenges in the development of treatments for ultra-rare diseases. Recent changes in financial and market conditions, along with evolving policy environments, have led many promising therapies to be shelved or delayed. The Accelerator aims to address this issue by taking on these underused programmes and advancing them efficiently through clinical trials, supported by the ClinDevNet network.
The therapies may be commercialised in various ways, including directly from academic or non-profit sources, through spin-out companies under an affiliated structure, or by licensing to suitable biotech partners.
Initial funding from Chiesi, BIAL, and other contributors will be used to complete the evaluation and launch of two to three lead programmes. Further fundraising is ongoing to support these and other projects in the pipeline. Revenue from licensing or commercial activities will be reinvested into the Accelerator to support more treatments as the model grows.
OTXL aims to become self-sustaining within four to six years. In doing so, it hopes to protect future ultra-rare disease therapies from market disruptions, expand its efforts, and accelerate the delivery of important treatments to patients who need them most.
Source: businesswire.com
